权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Kidney PCSK9 in nephrotic syndrome

肾病综合征中的肾脏 PCSK9

基本信息

批准号：
10316241
负责人：
Lionel Claudius Clement
金额：
$ 34.54万
依托单位：
RUSH UNIVERSITY MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-01-01 至 2024-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10316241
关键词：
Affinity Amiloride Animal Model Antibodies Archives Biopsy Blood Circulation Buffaloes Cell Line Cell surface Cells Cholesterol Confocal Microscopy Detection Development Diabetic Nephropathy Diagnosis Disease Duct (organ) structure Epithelial Cells Family Focal Segmental Glomerulosclerosis Gel Glomerulonephritis Hepatic Human Intestines Kidney Kidney Diseases Link Liver Longitudinal Studies Low Density Lipoprotein Receptor Mass Spectrum Analysis Membranous Glomerulonephritis Modeling Molecular Molecular Chaperones Mus Nephrosis Nephrotic Syndrome Patient Care Patients Pattern Pharmaceutical Preparations Phase Phosphorylation Plasma Play Post-Translational Protein Processing Proprotein Convertases Proteins Proteinuria Puromycin Aminonucleoside Rattus Recombinants Renal glomerular disease Rodent Rodent Model Role Sampling Serine Protease Serum Sodium Subtilisins Sulfate Testing Therapeutic Urine base collecting tubule structure db/db mouse epithelial Na+ channel gain of function mutation heart disease risk hypercholesterolemia hypocholesterolemia improved kidney biopsy member migration nephrotoxicity prevent protein expression sialylation standard care tissue archive two-dimensional

项目摘要

Summary / Abstract (max 30 lines): Nephrotic syndrome is a major manifestation of human glomerular disease, and patients with this condition develop large amounts of protein in the urine (proteinuria) and elevated levels of plasma cholesterol (hypercholesterolemia). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is well studied in the liver where it is implicated in the development of hypercholesterolemia but little is known about the link between kidney PCSK9 and hypercholesterolemia. Statins and/or PCSK9 antibodies are now considered the standard care for patients with hypercholesterolemia but this therapeutic approach only treats hypercholesterolemia once it is established and does not prevent the development of hypercholesterolemia. Recent studies from the applicant’s lab suggest that PCSK9 is expressed in the kidney, mainly in the cortical collecting duct (CCD) and that PCSK9 secreted from the CCD initiates hypercholesterolemia in nephrotic syndrome. In fact, PCSK9 expression is increased in the CCD in human focal and segmental glomerulosclerosis (FSGS) kidney biopsies compared to controls. This phenomenon was also noted in two animal models of FSGS. In this proposal, the PI will study molecular mechanisms of the origin of hypercholesterolemia of nephrotic syndrome and will identify the specific glycomic profile of CCD-secreted PCSK9. It will allow its detection and depletion during the early phase of hypercholesterolemia to prevent or reduce progression to the established phase. In Specific Aim 1, the applicant will study by confocal microscopy, the expression of CCD-PCSK9 in biopsies from nephrotic patients with other kidney diseases and corresponding animal models. In Specific Aim 2, the applicant will use mass spectrometry to identify the specific post-translational modification profile of PCSK9 secreted from the kidney CCD. The affinity of LDL receptor for different forms of recombinant PCSK9, that mimic liver or kidney secreted proteins, will also be assed. In Specific Aim 3, the applicant will study the effect of modulating CCD-PCSK9 expression and its depletion from plasma on sustained hypercholesterolemia in nephrotic syndrome.

摘要/摘要（最多30行）：